520A
J-Pharma Co.,Ltd.
ジェイファーマ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(-)
Mar 2026
-
Operating profit(thousand JPY)
Mar 2026
-3,710,176
Operating profit margin(-)
Mar 2026
-
Profit before tax(thousand JPY)
Mar 2026
-2,465,300
Profit(thousand JPY)
Mar 2026
-2,466,416
Total assets(thousand JPY)
Mar 2026
4,761,406
Cash and cash equivalents(thousand JPY)
Mar 2026
4,452,646
Cash flows from operating activities(thousand JPY)
Mar 2026
-2,248,727
Cash flows from investing activities(thousand JPY)
Mar 2026
-3,667
Cash flows from financing activities(thousand JPY)
Mar 2026
4,333,814
Return on equity(-)
Mar 2026
-
Equity ratio(%)
Mar 2026
85.4
Earnings per share(JPY per share)
Mar 2026
-195.08
Net assets per share(JPY per share)
Mar 2026
226.07
Dividend per share(-)
Mar 2026
-
Payout ratio(-)
Mar 2026
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.